Liminatus Pharma (LIMN) Assets Average (2025 - 2026)

Liminatus Pharma (LIMN) posted Assets Average of $1.7 million for Q1 2026, up 78.04% sequentially from $927602.0 in Q4 2025.

Liminatus Pharma (LIMN) Assets Average (2025 - 2026) Analysis & Trends

Liminatus Pharma has reported Assets Average for 2 years, with the latest figure at $1.7 million in Q1 2026.

Quarterly Assets Average changed N/A year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (changed N/A YoY) and the FY2025 annual result came in at $3.0 million, changed N/A from the prior year.
Assets Average grew to $1.7 million in Q1 2026 per LIMN's latest filing, from $927602.0 in the prior quarter.
Over five years, Assets Average peaked at $1.7 million in Q1 2026 and troughed at $927602.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets Avg. (Qtr)
1	Vertex Pharmaceuticals	139.69 Bn	131.84 Bn	2.84 Bn	26.95 Bn
2	Regeneron Pharmaceuticals	86.46 Bn	78.47 Bn	3.93 Bn	41.30 Bn
3	Argenx Se	65.62 Bn	60.44 Bn	1.37 Bn	-
4	Moderna	58.37 Bn	53.24 Bn	52.00 Mn	11.22 Bn
5	BeOne Medicines	42.17 Bn	37.07 Bn	1.53 Bn	8.86 Bn
6	Alnylam Pharmaceuticals	31.73 Bn	28.43 Bn	992.69 Mn	5.34 Bn
7	BioNTech SE	28.27 Bn	9.87 Bn	668.28 Mn	25.27 Bn
8	Insmed	27.58 Bn	26.42 Bn	358.27 Mn	2.09 Bn
9	Royalty Pharma	27.23 Bn	26.40 Bn	-	19.82 Bn
10	Liminatus Pharma	262.56 Mn	262.56 Mn	-	3.10 Mn

Download Data